A Phase II, 12-Week Study of ISIS 14083, An Antisense Inhibitor of HCV for the Treatment of Chronic Hepatitis C
A Phase II, 12-Week Study of ISIS 14083, An Antisense Inhibitor of HCV for the Treatment of Chronic Hepatitis C. Hepatology. 2002; 36(4):362A.